临床暂停的原因是，CIC 2期试验中，一名于2023年1月接受该疫苗的 非美国受试者自发报告了严重不良事件 （SAE）——运动神经病变。该试验于2023年7月完成，受试者于2024年9月报告SAE。

However, recent news represents a setback for Novavax's combined vaccine candidate. The U.S. Food and Drug Administration ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

疫苗制造商Novavax(NVAX.US)表示，欧盟委员会已授予其更新的Covid-19疫苗的营销授权。

投资慧眼Insights - 辉瑞对手、美国疫苗制造商诺瓦瓦克斯Novavax年中因与制药巨头赛诺菲的合作而逆转疫情后颓势，创下两日股价暴涨200%的「重生」传奇。而该公司近日因实验安全问题被美国FDA暂停临床试验，股价闪崩近20%。 周三（10月16日），诺瓦瓦克斯表示，在一名美国境外的试验参与者发生了严重运动神经病变后，美国食品药品监督管理局FDA暂停了这家公司的「流感/新冠联合疫苗」临床试验 ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...

在一名临床试验参与者发生严重不良事件後，Novavax(NVAX.US)遭美国食品和药物管理局暂停其实验性流感疫苗的开发，该股股价周三下挫20%。

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, ...